Sawai`s Generic Dimethyl Fumarate Receives Approval in the U.S.
Japanese generic major Sawai Pharmaceutical said on June 22 that it has entered into a codevelopment and exclusive license agreement with Neugen Pharma for the rights to manufacture and market the Tokai University spin-off's amyotrophic lateral sclerosis (ALS) drug candidate…
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has entered into an exclusive agreement with a pharmaceutical partner to market and distribute a group of six ophthalmic and otic ANDA products.
Upsher-Smith Laboratories, LLC (Upsher-Smith) today reported that its parent company, Japan-based Sawai Pharmaceutical Co., Ltd. (Sawai) will sell a 20 percent stake in its US subsidiary (Sawai America Inc.*) to Sumitomo Corporation of Americas (SCOA), a subsidiary of Sumitomo Corporation, one of Japan's leading general trading houses. Under the terms of the agreement, SCOA will acquire the stake for consideration of $211 million. The transaction is expected to close by the end of March 2018.
For decades, Japan’s Sawai family was content to keep the drug business they founded focused on its home market. Now, they are steering the country’s second-biggest maker of generic drugs through its first overseas acquisition in its 88-year history.
OSAKA -- Sawai Pharmaceutical will buy the generics business of U.S. drugmaker Upsher-Smith Laboratories for $1.05 billion, the Japanese company said Thursday, eager to make up for lost time after its first push into the American market stalled.
Sawai Usa's Generic Pitavastatin Calcium Receives Approval In US
With drop in sales last year, Sanofi is looking for newer measures to beef up its business in Japan. Sanofi's sales dropped by 11 percent year-on-year to 261.1 billion yen ($2.3 billion) in 2015. In Japan, Sanofi is eager to introduce new drugs as generics continue to eat its profits. Sanofi's widely prescribed antiplatelet drug Plavix (clopidogrel), for example, is challenged by the generic version from Tanabe and Sawai.
Japanese drug giant Towa Pharmaceuticals makes foray into the US markets banking on its new set of pills that can be taken without water. The tablets, manufactured with Ractab technology can be orally disintegrated and the Osaka company is seek approval with U.S. authorities for market approvals.
Japan's Nichi-Iko Pharmaceutical seeks to crack the U.S. market with brand-new drugs -- not the generic drugs the company is known for -- as the domestic market is expected to stop growing in the long run.